Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy.

[1]  K. Lee,et al.  Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. , 1996, Circulation.

[2]  R. Califf,et al.  Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. , 1995, Circulation.

[3]  L. Wilkins.  Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. , 1994, Circulation.

[4]  E. Antman.  Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. , 1994, Circulation.

[5]  Fibrinolytictherapytrialistsf.  Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[6]  F. Werf,et al.  One year followup from the GUSTO I trial , 1994 .

[7]  C. O'connor,et al.  A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1. , 1994, Journal of the American College of Cardiology.

[8]  Johan Herlitz,et al.  Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[9]  Gusto Angiographic Investigators.  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. , 1993, The New England journal of medicine.

[10]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[11]  J. Hsia,et al.  Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators. , 1992, Journal of the American College of Cardiology.

[12]  David Hunt,et al.  ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION , 1992 .

[13]  D. Collen,et al.  Plasma Fibrinopeptide A Levels in Patients With Acute Myocardial Infarction Treated With Alteplase: Correlation With Concomitant Heparin, Coronary Artery Patency, and Recurrent Ischemia , 1992, Circulation.

[14]  M. Pfisterer,et al.  Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. , 1992, British heart journal.

[15]  G. Hanique,et al.  Infusion of Heparin Conjunct To Streptokinase Accelerates Reperfusion of Acute Myocardial-infarction - Results of a Double-blind Randomized Study (osiris) , 1992 .

[16]  R. Collins,et al.  HEPARIN IN THE PRESENCE OR ABSENCE OF ANTIPLATELET THERAPY - AN OVERVIEW OF RANDOMIZED TRIALS IN ACUTE MYOCARDIAL-INFARCTION , 1992 .

[17]  H. Hellstrom.  Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. , 1991, Circulation.

[18]  D. Tate,et al.  Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. , 1990, The American journal of cardiology.

[19]  J. Hsia,et al.  A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. , 1990, The New England journal of medicine.

[20]  R. Califf,et al.  Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. , 1990, Circulation.

[21]  F. Klocke,et al.  Guidelines for the early management of patients with acute myocardial infarction , 1990 .

[22]  F. Klocke,et al.  ACC/AHA guidelines for the early management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (subcommittee to develop guidelines for the early manag , 1990, Circulation.

[23]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  MEDICAL SCIENCE GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction , 1990, The Lancet.

[24]  K. Lee,et al.  A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. , 1989, Circulation.

[25]  Isis Pilot Study Investigation.  Randomized factorial trial of high-dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction , 1987 .

[26]  J. Gore,et al.  The role of anticoagulant therapy in acute myocardial infarction. , 1984, American heart journal.